Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.49 |
| ▸ | CNR1 | P21554 | 7/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414792 | 0.74 | CRHR1 (0.64) | CRHR1 | |
| SCHEMBL7472347 | 0.73 | CRHR1 (0.51) | CRHR1CNR1 | |
| SCHEMBL4801849 | 0.73 | CNR1 (0.48) | CNR1CNR2CDC7DBF4CCNE1 | |
| SCHEMBL5414334 | 0.72 | CRHR1 (0.46) | CRHR1CNR1CNR2L3MBTL1 | |
| SCHEMBL5415195 | 0.72 | CRHR1 (0.47) | CRHR1CNR1CNR2 | |
| SCHEMBL6101843 | 0.71 | CRHR1 (0.55) | CRHR1HSD11B1 | |
| SCHEMBL5417698 | 0.71 | CNR1 (0.51) | CRHR1CNR1CNR2 | |
| SCHEMBL5421171 | 0.70 | HTR2C (0.46) | CRHR1HSD11B1 | |
| SCHEMBL5412305 | 0.70 | CRHR1 (0.48) | CRHR1CNR1CNR2 | |
| SCHEMBL5404091 | 0.70 | FPR2 (0.43) | CRHR1CNR1CNR2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | claimed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | claimed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | CRHR1 27/4885CNR1 66/4885CNR2 72/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | CRHR1 27/4885CNR1 66/4885CNR2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.